Published in Clin Cancer Res on January 01, 2009
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One (2010) 1.66
Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst (2010) 1.65
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov (2013) 1.63
Targeting BRAF for patients with melanoma. Br J Cancer (2010) 1.56
Pharmacological targeting of the Hsp70 chaperone. Curr Top Med Chem (2009) 1.51
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol (2010) 1.38
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol (2012) 1.36
Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One (2011) 1.31
To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Med Chem (2009) 1.29
Treating breast cancer in the 21st century: emerging biological therapies. J Cancer (2013) 1.26
EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets (2010) 1.25
A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin Appl (2011) 1.25
Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer (2009) 1.23
Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov (2009) 1.21
Heat shock protein 90α (Hsp90α) is phosphorylated in response to DNA damage and accumulates in repair foci. J Biol Chem (2012) 1.10
Hsp90 modulates CAG repeat instability in human cells. Cell Stress Chaperones (2010) 1.09
Development of a Grp94 inhibitor. J Am Chem Soc (2012) 1.06
Inhibition of heat-shock protein 90 reduces Ebola virus replication. Antiviral Res (2010) 1.04
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs (2012) 1.03
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol (2012) 1.02
Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Curr Top Med Chem (2009) 1.02
Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Int J Oncol (2011) 1.02
17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2. Breast Cancer Res (2010) 1.01
Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy. Curr Mol Med (2012) 0.99
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci U S A (2010) 0.99
c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway. J Biol Chem (2011) 0.97
High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888. PLoS One (2011) 0.97
Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. Oncologist (2013) 0.97
Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog (2012) 0.95
Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood (2012) 0.95
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Invest New Drugs (2013) 0.94
LRRK2 in Parkinson's disease: function in cells and neurodegeneration. FEBS J (2009) 0.93
Mechanistic insight into the ability of American ginseng to suppress colon cancer associated with colitis. Carcinogenesis (2010) 0.92
Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope (2011) 0.91
Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally. Int Rev Cell Mol Biol (2013) 0.90
Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction. PLoS One (2012) 0.89
A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res (2013) 0.89
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition. Clin Cancer Res (2011) 0.88
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. Clin Cancer Res (2010) 0.88
Evidence of prognostic relevant expression profiles of heat-shock proteins and glucose-regulated proteins in oesophageal adenocarcinomas. PLoS One (2012) 0.87
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs (2014) 0.87
MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors. Oncotarget (2014) 0.87
The Skp chaperone helps fold soluble proteins in vitro by inhibiting aggregation. Biochemistry (2012) 0.86
Molecular imaging of apoptosis: from micro to macro. Theranostics (2015) 0.86
Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist (2011) 0.85
Heterozygous yeast deletion collection screens reveal essential targets of Hsp90. PLoS One (2011) 0.85
The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells. Clin Exp Med (2012) 0.84
Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors. Autophagy (2012) 0.83
Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. PLoS One (2013) 0.82
Targeting the 90 kDa heat shock protein improves photodynamic therapy. Cancer Lett (2009) 0.82
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Target Oncol (2014) 0.82
Targeting Cell Survival Proteins for Cancer Cell Death. Pharmaceuticals (Basel) (2016) 0.81
Heat shock protein 90 (hsp90) expression and breast cancer. Pharmaceuticals (Basel) (2012) 0.81
Changing strategies for target therapy in gastric cancer. World J Gastroenterol (2016) 0.81
A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. Br J Pharmacol (2014) 0.80
Target therapy in metastatic pheochromocytoma: current perspectives and controversies. Oncol Rev (2014) 0.80
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs (2010) 0.80
Recent advances in the HER2 targeted therapy of gastric cancer. World J Clin Cases (2015) 0.80
Inhibition of the ecto-beta subunit of F1F0-ATPase inhibits proliferation and induces apoptosis in acute myeloid leukemia cell lines. J Exp Clin Cancer Res (2012) 0.79
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells. Cancers (Basel) (2015) 0.79
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 0.78
A combined molecular modeling study on a series of pyrazole/isoxazole based human Hsp90α inhibitors. J Mol Model (2011) 0.78
Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening. PLoS One (2013) 0.77
Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1. Oncotarget (2015) 0.76
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors. Cancer Chemother Pharmacol (2012) 0.75
Neuroblastoma treatment in the post-genomic era. J Biomed Sci (2017) 0.75
NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo. Onco Targets Ther (2017) 0.75
HSP90 Inhibitor Geldanamycin as a Radiation Response Modificator in Human Blood Cells. Dose Response (2015) 0.75
Efficiency of AUY922 in mice with adult T-cell leukemia/lymphoma. Oncol Lett (2016) 0.75
Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery. Invest New Drugs (2017) 0.75
Screening of multiple myeloma by polyclonal rabbit anti-human plasmacytoma cell immunoglobulin. PLoS One (2013) 0.75
Selection and Characterization of Single Chain Antibody Fragments Specific for Hsp90 as a Potential Cancer Targeting Molecule. Int J Mol Sci (2015) 0.75